The accurate assessment of nodal involvement in prostate cancer is crucial to planning treatment, yet there is a shortage of noninvasive imaging techniques capable of visualizing nodal lesions directly. This study demonstrates the feasibility of using recombinant human adenoviral vectors to detect nodal metastases in a human prostate cancer model. This was achieved by the prostate-restricted expression of optical and positron emission tomography (PET) imaging reporter genes by the viral vector coupled with the innate lymphotropic properties of adenovirus. We show that peritumoral administration of these vectors results in the direct detection of reporter gene expression in metastatic lesions within sentinel lymph nodes. Notably, this approach parallels the current lymphoscintigraphy method but enables the direct PET visualization of sentinel lymph node metastases, eliminating the need for invasive lymphadenectomy. These findings may lead to more effective diagnostic and therapeutic strategies for individuals with advanced-stage prostate cancer.
The accurate assessment of nodal involvement in prostate cancer is crucial to planning treatment, yet there is a shortage of noninvasive imaging techniques capable of visualizing nodal lesions directly. This study demonstrates the feasibility of using recombinant human adenoviral vectors to detect nodal metastases in a human prostate cancer model. This was achieved by the prostate-restricted expression of optical and positron emission tomography (PET) imaging reporter genes by the viral vector coupled with the innate lymphotropic properties of adenovirus. We show that peritumoral administration of these vectors results in the direct detection of reporter gene expression in metastatic lesions within sentinel lymph nodes. Notably, this approach parallels the current lymphoscintigraphy method but enables the direct PET visualization of sentinel lymph node metastases, eliminating the need for invasive lymphadenectomy. These findings may lead to more effective diagnostic and therapeutic strategies for individuals with advanced-stage prostate cancer.
The pathological findings of aggressive prostate cancer have been well documented in a large series of prostatectomy subjects 1, 2 . Among the adverse pathologic features, the presence of pelvic lymph node metastasis is the strongest predictor of poor outcome 3 . For instance, the 10-year progression-free survival probabilities were 79% for organconfined disease, 53% for disease with extraprostatic extension and only 12% for disease with lymph node metastases 1 . Therefore, methods to accurately detect nodal metastasis would be very helpful for tumor staging and in formulating the most appropriate treatment.
Despite the importance of nodal status of prostate cancer, methods to assess pelvic lymph nodes are suboptimal. At the present time, accurate lymph node staging can only be determined by pelvic lymphadenectomy 4 . Potential complications of this procedure include lymphoceles, lymphedema, venous thrombosis and pulmonary embolism, with an estimated incidence of 20% 5 . Conventional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are useful in evaluating anatomical abnormalities; however, neither technology can differentiate between adenopathy related to inflammation and that caused by deposition of malignant cells 6, 7 . Recently, a new iron oxide paramagnetic nanoparticle was developed as an MRI contrast agent to identify tumorinfiltrated lymph nodes in individuals with prostate cancer 8 . However, this technology relies on an indirect identification of metastasis in which nodal infiltration of macrophages that have engulfed the magnetic particles highlight metastatic regions devoid of signal.
Advancements in sentinel lymph node (SLN) mapping have come mainly from the melanoma and breast cancer fields 9, 10 . The current method of intraoperative lymphoscintigraphy entails the use of a g camera to monitor the transit of a technetium-99m ( 99m Tc)-filtered sulfur colloid particle from the peritumoral injection site into the SLN, which is then harvested for histopathological examination 11 . The size and surface properties of colloidal particles determine their suitability as lymphangiographic agents 11, 12 . Studies have implicated the ability of human adenovirus (serotype 5) to be effectively transported into the lymphatic circulation [13] [14] [15] . The negatively charged capsid and size (B100 nm) probably favor the entry of adenoviral particles into the lymphatics.
We have developed several prostate-specific adenoviral vectors that express imaging reporter genes under the control of a highly amplified prostate-specific antigen (PSA) promoter system, known as the twostep transcriptional activation (TSTA) system 16, 17 . Here we demonstrate that adenoviral vectors effectively function as lymphotropic agents and can mediate gene transfer into the metastatic prostate cancer cells in the draining lymph nodes. Such a prostate-specific gene expression imaging modality may be very helpful toward improving the clinical management of advanced stage prostate cancer.
RESULTS
Adenovirus traffics via lymphatics to regional lymph nodes As described extensively in the rat, injection of colloidal dyes into the lymphatic-rich front footpad results in their accumulation in the ipsilateral brachial and axillary nodes 18 . To verify that adenoviruses also traverse through the lymphatics, we injected fluorescently tagged AdTSTA-fl, an adenoviral vector expressing firefly luciferase, in the forepaw. After 24 h, we detected the particles in the brachial lymph nodes by immunofluorescence microscopy (Fig. 1a) . The number of viral genomes transported to and retained in the brachial node after 24 h averaged about 60,000 copies, yielding an estimated efficiency of delivery of less than 0.1% (Fig. 1b) . We next investigated whether the virus was transported to the lymph nodes as free infectious virus. After paw-directed injection of adenoviral vector, the draining lymph nodes were isolated and gently disrupted. The lymph node supernatants were applied to LNCaP prostate cancer cells to evaluate transduction efficiency. In concordance with the PCR distribution data (Fig. 1b) , transduction activity (luciferase bioluminescence) was present in the ipsilateral brachial and axillary lymph node but not in the contralateral nodes (Fig. 1c) .
To explore the feasibility of the adenoviral lymphangiographic approach in cancerous prostate glands, we examined whether virus could effectively drain to regional lymph nodes in the mouse prostate Pten tumor suppressor gene knockout model 19 . This Pten À/À model effectively recapitulates the clinical characteristics of prostate cancer progression, from preneoplastic lesions to frank carcinoma and metastatic disease 19 . The carcinomatous prostate glands from 10-weekold Pten À/À mice are enlarged compared to those from wild-type littermates (Fig. 1d) . At this age, Pten À/À mice show large lymphatics within stromal regions between cancerous ductules (Fig. 1e) . One hour after injecting AdTSTA-fl into each dorsolateral lobe, we observed accumulation of virus within regional lymph nodes (Fig. 1f,g ). Approximately 1% of the injected dose was recovered in the periaortic lumbar nodes, with a lesser amount in more distant mesenteric and renal lymph nodes. Collectively, these data suggest that adenovirus can function as a lymphotropic agent while retaining gene transfer activity within the targeted lymph nodes.
We surmised that macrophages would not be an effective cellular vehicle for the adenoviral vectors, as the infectivity of mouse macrophage cell lines is more than 10,000 times lower than in a prostate carcinoma cell line ( Supplementary Fig. 1a online) . Further, extensive in vivo applications have shown the selective expression of TSTA imaging reporter vectors in prostate cells positive for androgen receptor (AR) and PSA and not in cells of other tissue origin, such as macrophages and hepatocytes 16, 17, 20, 21 ( Supplementary Fig. 1b,c) . Moreover, TSTA vector-mediated transgene expression was observed only in tumor cells and not in the associated F4/80 + macrophages ( Supplementary Fig. 1b) .
Lymph node metastasis model of prostate cancer
Our recent findings have shown that the lymphangiogenic vascular endothelial growth factor-C (VEGF-C) promotes lymphatic metastasis in our prostate cancer models 22 . The androgen-dependent, AR + PSA + LAPC-9 (Los Angeles prostate cancer series 9) xenograft model is useful for this diagnostic imaging study because, upon induced expression of VEGF-C, this tumor (LAPC-9-VEGF-C-GFP) shows consistent lymphatic metastasis when implanted subcutaneously (Fig. 2) 22, 23 . The tumor cells, transduced with a lentivirus encoding Renilla luciferase (RL) as a reporter gene (LAPC-9-VEGF-C-GFP-RL), enabled bioluminescence imaging of tumor growth (Fig. 2a) and sensitive quantification of nodal metastases (Fig. 2b,c) . Moreover, the volume of nodal infiltration could be adjusted with resection of the primary tumor (Fig. 2a,d,e) . Without primary tumor resection, micrometastases in the brachial or axillary node were consistently observed when the tumors reached about 1 cm in diameter at 3À4 weeks after implantation (Fig. 2a,b) . However, if the primary tumors were surgically resected and disseminated lesions were allowed to grow for an additional 30À40 d, then large macroscopic metastatic lesions developed, ultimately infiltrating the entire lymph node (Fig. 2d,e) . This large expansion of the nodal metastases can be Detecting macrometastasis in draining lymph nodes Despite the above noted inefficient degree of vector delivery to the axillary lymph nodes by paw-directed injection, we selected this method to show the principle of our approach for the following reasons. First, the paw-directed administrations consistently drained to brachial and axillary nodes (Fig. 1) , which were the precise dissemination sites of the subcutaneous prostate tumors implanted in the upper back. Second, the forepaw is at a sufficient distance from the target tissue to ensure a lymphatic route of vector distribution and to rule out random diffusion to the regional target. Third, injection at the forepaw allows for accurate differentiation between luminescent signal emitted from the injection site and that emitted from the targeted lymph node. To visualize the nodal metastasis by noninvasive imaging, we employed an adenoviral vector capable of expressing an imaging reporter gene at a robust level and in a prostate-specific manner 16 (Fig. 3a) . The specificity of AdTSTAÀfl was retained in the paw-directed injection as compared to a constitutive CMV promoter driven vector (Supplementary Fig. 1c) . The observed paw signals could be attributed to the great magnitude of extravasated vector that remained at the injection site. We tested the diagnostic capabilities of prostate-specific imaging vectors by bioluminescence imaging (Fig. 3b) and PET (Fig. 3c) in mice expected to bear macroscopic nodal lesions. After paw-directed administration of AdTSTAÀfl, we detected a clear optical signal in the axillas of tumor-bearing mice but not in controls (Fig. 3b) . Considering that specific and precise three-dimensional localization of nodal metastasis will be of great clinical use, we assessed the utility of a prostate-specific TSTA PET reporter vector (AdTSTAÀsr39tk) 17 in conjunction with its tracer 9-(4-[ 18 F]fluoro-3-hydroxymethylbutyl) guanine ( 18 FHBG). Injecting AdTSTAÀsr39tk into both forepaws produced a positive signal in the ipsilateral but not contralateral axilla (Fig. 3c) . The presence of disseminated prostate tumor cells in the ipsilateral brachial lymph node was confirmed by the node's enlarged size, by its GFP fluorescent signal and by histological identification of extensive tumor cell infiltration (Fig. 3d,e) . The maximum diameter of the infiltrated node was 2.54 mm, two-to threefold larger than the nonmetastatic contralateral node. Tumor celllocalized expression of sr39tk was verified in the respective lymph nodes by immunohistological staining (Fig. 3e) .
Direct detection of occult lymph node metastases
Having shown the ability to detect macroscopic nodal lesions, we proceeded to determine the ability of our gene expression vector to detect microscopic metastases. A cohort of 12 mice bearing LAPC-9-VEGF-C-GFP-RL tumors of 1 cm diameter on the right upper back was divided into two subgroups that received either 1 Â 10 8 or 1 Â 10 7 PFU of AdTSTAÀfl in both paws (Fig. 4a,b) . A specific signal was generated only in the ipsilateral axilla of mice that received the higher dose of vector (Fig. 4a,b) . This finding suggests that the lower dose of virus was insufficient to produce a visible optical signal for the occult metastasis.
We next investigated delivering the AdTSTAÀsr39tk in a manner emulating the clinical method of lymphoscintigraphy 11 . After injection around the subcutaneous LAPC-9-VEGF-C-GFP-RL tumor, the viral particles would be expected to drain to the SLN and transduce the metastatic prostate tumor cells. Indeed, robust 18 FHBG PET signals were detected in the tumor and the draining axillary lymph node (Fig. 4c) . The PET signal of the tumor and the anterior axillary node can be clearly distinguished by sagittal and transverse tomographic views (Fig. 4c) and a three-dimensional rendered digital movie (Supplementary Video 2 online). Immediately after the PET-CT scan, ipsilateral and contralateral lymph nodes were removed, and their bioluminescence and radioactivity were measured (Fig. 4d) .
Comparison of ex vivo radioactive signals showed at least twice the counts per minute per gram tissue in the ipsilateral over the contralateral nodes (Fig. 4d) . Moreover, the elevated radioactive tracer activity also correlated with the presence of tumor cells, as verified by the Renilla luciferase activity (Fig. 4d) . The quantification of PET signals in all three mice showed increased tracer uptake in the ipsilateral axillary region of interest over the contralateral side (Fig. 4e) . Ex vivo Renilla luciferase bioluminescence signals of the isolated lymph nodes again confirmed the presence of disseminated tumor cells in all three mice examined (Fig. 4f) . Collectively, the data suggest that this tumor-directed vector delivery method seems to reach the SLN efficiently, reinforcing the potential use of adenovirus as a lymphangiographic mapping agent in ascertaining nodal status.
Detecting lymph node metastasis in an orthotopic xenograft
The intraprostatic implanted LAPC-9-VEGF-C-GFP-RL tumors show an extensive network of peritumoral lymphatics extending into the margin of the tumor (Fig. 5a) . Notably, even without forced VEGF-C expression, the orthotopic implanted LAPC-9 and CWR22Rv-1 prostate tumors showed extensive peritumoral lymphatics ( Supplementary Fig. 2 online) . However, the incidence of lymphatic metastasis in these models is less predictable than in the LAPC-9-VEGF-C model. Therefore, we used the VEGF-C overexpression model to facilitate detection of metastasis.
Fifteen days after tumor implantation, we injected mice with AdTSTA-fl in each footpad to target lymph nodes involved in prostate cancer metastasis (that is, inguinal, iliac and lumbar) 18 . Imaging of the whole mouse showed prominent Renilla luciferase signal emanating from the orthotopic tumor (Fig. 5b) . Vector-directed firefly luciferase signals were able to identify the superficial nodes. However, owing to the photon scattering limitations, optical signals emanating from the deeper pelvic nodes would be difficult to discern in whole-animal imaging. Thus, we harvested the regional lymph nodes and imaged them ex vivo, and the periaortic node had the highest firefly luciferase signal (Fig. 5c) . Histological examination of this node showed a focus of subcapsular metastasis (Fig. 5d) , which was verified by human cytokeratin staining. To estimate the lesion size and the number of tumor cells in this involved node, we sectioned through the entire node. The maximum diameter of the lesion was B250 mm, containing B400 tumor cell nuclei in the largest section, which gives a conservative estimate of a maximum of 4,000 tumor cells in the entire lesion.
DISCUSSION
The status of lymph node metastasis is crucial for prostate cancer staging and treatment planning. However, the current procedures for acquiring this information are imprecise and invasive. A one-step, noninvasive imaging technology that can specifically visualize SLN metastasis would be of great value to the field. In this study, a recombinant replication-defective adenovirus served as the vehicle to deliver an imaging reporter gene to the tumor cells. An essential component of this technology is the ability of the adenovirus to function as a lymphotropic agent that is transported effectively to the draining lymph nodes as a free and infectious particle capable of transducing resident tumor cells and visualizing both large macroscopic and occult nodal lesions. We surmised that it is the robust, yet prostate-selective expression capability of the amplified TSTA vector that enables the direct imaging of the nodal metastases 16, 17, 21 . In one application, tumor-directed administration of the PET reporter vector (AdTSTA-sr39tk) produced specific 18 FHBG PET signals in the involved SLNs. To our knowledge, this is the first report detailing the lymphotropic and the selective gene expression capability of adenoviral particles to directly detect nodal metastases with PET. Although the issues regarding imaging sensitivity remain to be fully elucidated, the results presented here (Fig. 3c) suggest that this genetic biomarker-based PET was able to decisively seek out lymph node metastasis in a mouse bearing 2.5-mm lymph node lesions. Currently, the clinical lymphotropic MRI (LMRI) method is capable of detecting lesions 5-10 mm in diameter 8 . Furthermore, the results of tumor-directed AdTSTA-sr39tk administration (Fig. 4c) suggest that this technology has the potential to directly image microscopic metastases.
Extensive studies show that intravenous administration of adenoviral vectors results in substantial vector sequestration in the liver and reticuloendothelial system 13, 24 . This biodistribution pattern points to the ineffectiveness of adenovirus to target lymphatic circulation after systemic administration. In contrast, historical evidence indicates an innate affinity of adenovirus for the lymphatic system. Adenovirus can produce persistent infections in lymphoid organs such as the adenoid, from which the first adenovirus was isolated 13 . An additional advantage of the adenoviral vectormediated gene transfer approach is the prospect of inducing tumoricidal activity. For example, in addition to functioning as a PET reporter gene, the gene encoding the sr39tk reporter also acts as a suicide gene in the presence of the prodrug ganciclovir 25 . In fact, we have previously used the dual PET imaging and therapeutic function of AdTSTA-sr39tk to treat prostate tumors 21 . It is also noteworthy that a wide range of tissue-and tumorspecific promoters have been successfully incorporated in adenoviral vectors to target selective types of cancer 14, 26 . With this issue in mind, we recently developed a TSTA vector driven by the tumor-selective mucin-1 promoter and showed its feasibility in detecting SLN metastasis in an orthotopic breast tumor model (S. Huyn, J.B.B., M.S. and L.W., unpublished data). Hence, the adenoviral lymphangiographic imaging technology described in this study could be readily applied to melanoma and breast cancer, where determination of SLN status is also a key component of treatment planning.
Recent studies by our group and others have suggested that lymphatic dissemination also promotes subsequent systemic metastasis in experimental models 22, [27] [28] [29] . Clinical experience suggests that meticulous pelvic lymph node resection not only provides diagnostic information but also has a positive impact on prolonging disease-free survival 30 . Collectively, these findings highlight the necessity for accurate noninvasive detection of lymph node metastasis. The current gene expression-and biomarker-based method holds promise to improve the specificity of diagnostic imaging of nodal metastasis of prostate cancer. Moreover, coupling detection and suicide-gene therapy would enable not only the accurate assessment of lymph node status, but also the prospect of preventing metastatic outgrowth and systemic spread. Therefore, we consider this study is of utmost clinical relevance and expect it to have considerable influence on the development of new diagnostic and therapeutic options for men with prostate cancer.
METHODS
Mouse handling. All handling of mice was performed in accordance with the University of California, Los Angeles Animal Research Committee guidelines.
Adenoviral constructs and lymphatic trafficking. The construction and propagation of adenoviral vectors has been described previously 17 . AdTSTAfl was labeled with succinimidyl esters amine-reactive Alexa-Fluor 555 (AF555) fluorescent dye according to the manufacturer's recommendations (Molecular Probes/Invitrogen). Twenty-four hours after injecting AF555-AdTSTA-fl virus (1 Â 10 7 PFU per 10 ml) in the forepaw, we harvested the mouse's axillary and brachial lymph nodes, mounted them as 4-mm frozen sections, briefly fixed them with ice-cold methanol and stained them with DAPI (Vector Laboratories). We verified the presence of viral particles with a Carl Zeiss LSM 310 laser scanning confocal microscope.
To isolate virus particles from lymph nodes, we injected mice (n ¼ 3) in the forepaw with 1 Â 10 8 PFU AdTSTA-fl (20 ml in PBS). We dissected lymph nodes and placed them in microcentrifuge tubes with 250 ml of RPMI medium. We disrupted nodal capsules by gentle agitation followed by brief vortexing and centrifugation at 2,500g for 5 min. We removed the supernatants and applied them to 1 Â 10 5 LNCaP cells per well growing in a 24-well plate. We measured luciferase activity 4 d after infection by in vitro bioluminescence assay (Promega). We measured total protein by Coomassie Plus protein assay (Pierce Biotechnology).
Intraprostatic adenovirus administration. We exposed the prostates of 10-week-old Pten À/À mice by making a small abdominal incision and gently exposing the seminal vesicles. We injected the enlarged dorsolateral prostate with 1 Â 10 8 PFU adenovirus per lobe, followed by closure of the surgical incision. After 1 h, we killed the mice and dissected regional periaortic, renal and mesenteric lymph nodes.
Real-time PCR. We harvested lymph nodes and extracted total DNA by a column purification procedure according to the manufacturer's suggested protocol (DNeasy Kit, Qiagen). We used purified adenovirus DNA (1 Â 10 8 PFU) as a standard curve. We amplified exactly 2 ml per sample in triplicate with primers specific for the E2 region of adenovirus as previously described 13 Xenograft model of lymph node metastasis. We maintained the LAPC-9 xenograft by serial passage in SCID/Beige (natural killer cell-deficient) mice (Taconic). We processed freshly dissected LAPC-9 tumors (1,000 mm 3 ) into single-cell suspensions 17 and transduced them with the designated lentivirus, pCCL-VEGFC-IRES-GFP and pCCL-RL 22 . LAPC-9-VEGF-C cells (1 Â 10 6 ) were implanted with Matrigel (BD Biosciences) on the right shoulder of SCID/Beige mice. We allowed the tumors to reach the ethical limit of 1.5 cm in diameter, at which point we performed tumor resection or killed the mice. We monitored metastasis after tumor resection for up to an additional 40 d by palpation, optical imaging of Renilla luciferase activity or 18 FLT PET imaging. For the orthotopic model, we injected 2.5 Â 10 5 LAPC-9-VEGF-C-GFP-RL cells with Matrigel into each dorsolateral prostatic lobe.
Mouse imaging experiments. We injected mice in the paw with 20 ml of adenovirus in PBS and then gently massaged the paw for 5 min. We imaged mice 4 d after virus administration. Briefly, mice were anesthetized, injected with D-luciferin (150 mg kg -1 intraperitoneally) and imaged with a bioluminescent imager (IVIS 100; Xenogen) after 20 min. We analyzed data with IGOR-PRO Living Image software as described previously 20 . For PET studies, we injected mice (n ¼ 3) with macroscopic lymph node metastases in the forepaw with AdTSTA-sr39tk (2 Â 10 8 PFU). We injected mice receiving peritumoral administration of AdTSTA-sr39tk with 1 Â 10 8 PFU (30 ml) every day for 5 d. Six days after the first or only injection of AdTSTA-sr39tk, we imaged the mice by PET after having given them a single intravenous bolus (B250 mCi) of 18 FHBG or 18 FLT. One hour after tracer injection, we scanned the mice for 10 min in a Focus 220 micro-PET scanner (Siemens Preclinical Solutions). PET images were created by filtered back projection at 0.4-mm pixel size with 0.8-mm slice thickness. We then transferred the mice to a micro-CT scanner (MicroCAT II, Siemens Preclinical Solutions) and imaged them over 7 min using 70-kVp, 500-ms exposures and 3601 rotation to create images with 200-micron voxel size. We created fused PET-CT images with previously described methods 31 .
Positron emission tomography and computed tomography analysis. We analyzed PET and CT datasets with AMIDE software 32 . All PET datasets were converted to percentage injected dose per gram on the basis of a phantom calibration constant, total injected dose, decay rate for 18 F and an assumption of 1 g ml -1 tissue density. We drew regions of interest over the site of injection as well as on ipsilateral and contralateral axilla. We used the average of the maximum pixel values from representative regions to calculate percentage injected dose per gram.
Immunohistochemistry. We fixed tissues in 3% paraformaldehyde and embedded them in paraffin. We stained sections (5 mm) with antibody to the epithelial marker cytokeratin (Biogenex) or to the lymphatic marker Lyve-1 (RELIATech) as previously described 22 . We detected horseradish peroxidaseconjugated secondary antibody to the cytokeratin antibody with 3,3-diaminobenzidine tetrahydrochloride substrate (Liquid DAB Substrate Pack, Biogenex). We performed macrophage staining with rat antibody to mouse F4/80 (Serotec). We detected red fluorescent protein (RFP) from paraffinembedded sections with rabbit antibody to RFP (Rockland Immunochemicals). We performed secondary detection of F4/80 and RFP with biotinylated antibodies to mouse and rabbit IgG, respectively (Vector Laboratories).
Rabbit antibody to herpes simplex virus thymidine kinase (HSV-tk) was a kind gift from M. Black, and we used it on 3% paraformaldehyde-fixed, paraffinembedded tissue sections by incubating it at a 1:15,000 dilution overnight at 4 1C. We used multilink antibody (1:20, Biogenex) for secondary detection.
Statistical analyses. All error bars in graphical data represent means ± s.e.m. We used Student's two-tailed t-test for determination of statistical relevance between groups and considered P o 0.05 significant.
Note: Supplementary information is available on the Nature Medicine website.
